{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T15:52:31Z","timestamp":1765295551554,"version":"3.40.5"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,11]],"date-time":"2025-05-11T00:00:00Z","timestamp":1746921600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,5,11]],"date-time":"2025-05-11T00:00:00Z","timestamp":1746921600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"NIH","award":["P30CA014236","K12AR084231"],"award-info":[{"award-number":["P30CA014236","K12AR084231"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1007\/s10549-025-07717-3","type":"journal-article","created":{"date-parts":[[2025,5,11]],"date-time":"2025-05-11T06:28:59Z","timestamp":1746944939000},"page":"161-172","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Survival outcomes after pathologic complete response with neoadjuvant endocrine therapy vs. neoadjuvant chemotherapy: a retrospective national database study"],"prefix":"10.1007","volume":"212","author":[{"given":"Tori C.","family":"Nierenberg","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samantha M.","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ian","family":"Halliday","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Astrid","family":"Botty van den Bruele","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akiko","family":"Chiba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kendra J.","family":"Modell Parrish","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hannah E.","family":"Woriax","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maggie L.","family":"DiNome","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kelly E.","family":"Westbrook","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7411-0558","authenticated-orcid":false,"given":"Jennifer K.","family":"Plichta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,5,11]]},"reference":[{"issue":"6","key":"7717_CR1","doi-asserted-by":"publisher","first-page":"e210891","DOI":"10.1001\/jamasurg.2021.0891","volume":"156","author":"S Samiei","year":"2021","unstructured":"Samiei S, Simons JM, Engelen SME, Beets-Tan RGH, Classe J-M, Smidt ML (2021) Axillary pathologic complete response after neoadjuvant systemic therapy by breast cancer subtype in patients with initially clinically node-positive disease. JAMA Surg 156(6):e210891","journal-title":"JAMA Surg"},{"issue":"9","key":"7717_CR2","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1093\/jnci\/93.9.684","volume":"93","author":"B Fisher","year":"2001","unstructured":"Fisher B, Dignam J, Bryant J, Wolmark N (2001) Five versus more than five years of tamoxifen for lymph node-negative breast cancer: updated findings from the national surgical adjuvant breast and bowel project B-14 randomized trial. JNCI J Natl Cancer Inst 93(9):684\u2013690","journal-title":"JNCI J Natl Cancer Inst"},{"issue":"9938","key":"7717_CR3","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/S0140-6736(13)62422-8","volume":"384","author":"P Cortazar","year":"2014","unstructured":"Cortazar P, Zhang L, Untch M, Mehta K, Costantino JP, Wolmark N et al (2014) Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. The Lancet 384(9938):164\u2013172","journal-title":"The Lancet"},{"issue":"15","key":"7717_CR4","doi-asserted-by":"publisher","first-page":"1796","DOI":"10.1200\/JCO.2011.38.8595","volume":"30","author":"G Von Minckwitz","year":"2012","unstructured":"Von Minckwitz G, Untch M, Blohmer JU, Costa SD, Eidtmann H, Fasching PA, Gerber B, Eiermann W, Hilfrich J, Huober J, Jackisch C (2012) Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. J Clin Oncol 30(15):1796\u20131804","journal-title":"J Clin Oncol"},{"issue":"3","key":"7717_CR5","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1007\/s10549-023-07152-2","volume":"203","author":"D Moldoveanu","year":"2024","unstructured":"Moldoveanu D, Hoskin TL, Day CN, Schulze AK, Goetz MP, Boughey JC (2024) Nodal pCR and overall survival following neoadjuvant chemotherapy for node positive ER+\/Her2- breast cancer. Breast Cancer Res Treat 203(3):419\u2013428","journal-title":"Breast Cancer Res Treat"},{"issue":"11","key":"7717_CR6","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.1001\/jamaoncol.2016.1897","volume":"2","author":"LM Spring","year":"2016","unstructured":"Spring LM, Gupta A, Reynolds KL, Gadd MA, Ellisen LW, Isakoff SJ et al (2016) Neoadjuvant endocrine therapy for estrogen receptor-positive breast cancer. JAMA Oncol 2(11):1477","journal-title":"JAMA Oncol"},{"issue":"17","key":"7717_CR7","doi-asserted-by":"publisher","first-page":"2342","DOI":"10.1200\/JCO.2010.31.6950","volume":"29","author":"MJ Ellis","year":"2011","unstructured":"Ellis MJ, Suman VJ, Hoog J, Lin L, Snider J, Prat A et al (2011) Randomized Phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor-rich stage 2 to 3 breast cancer: clinical and biomarker outcomes and predictive value of the baseline PAM50-based Int. J Clin Oncol 29(17):2342\u20132349","journal-title":"J Clin Oncol"},{"issue":"1","key":"7717_CR8","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1007\/s10549-021-06153-3","volume":"188","author":"KU Park","year":"2021","unstructured":"Park KU, Gregory M, Bazan J, Lustberg M, Rosenberg S, Blinder V et al (2021) Neoadjuvant endocrine therapy use in early stage breast cancer during the covid-19 pandemic. Breast Cancer Res Treat 188(1):249\u2013258","journal-title":"Breast Cancer Res Treat"},{"issue":"12","key":"7717_CR9","doi-asserted-by":"publisher","first-page":"2838","DOI":"10.1158\/1078-0432.CCR-19-3492","volume":"26","author":"LM Spring","year":"2020","unstructured":"Spring LM, Fell G, Arfe A, Sharma C, Greenup R, Reynolds KL et al (2020) Pathologic complete response after neoadjuvant chemotherapy and impact on breast cancer recurrence and survival: a comprehensive meta-analysis. Clin Cancer Res 26(12):2838\u20132848","journal-title":"Clin Cancer Res"},{"key":"7717_CR10","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1097\/XCS.0000000000001214","volume":"240","author":"EB Habermann","year":"2025","unstructured":"Habermann EB, Day CN, Palis BE, Plichta JK, Wasif N, Weigel RJ, Boughey JC (2025) American college of surgeons cancer program annual report from 2021 participant user file. Am Coll Surgeons 240:95","journal-title":"Am Coll Surgeons"},{"issue":"1","key":"7717_CR11","doi-asserted-by":"publisher","first-page":"e35525","DOI":"10.1002\/cncr.35525","volume":"131","author":"JK Plichta","year":"2024","unstructured":"Plichta JK, Thomas SM, Chanenchuk TC, Chan K, Hyslop T, Hwang ES, Greenup RA (2024) Comparison of incident breast cancer cases in the largest national US tumor registries. Cancer 131(1):e35525","journal-title":"Cancer"},{"issue":"10","key":"7717_CR12","doi-asserted-by":"publisher","first-page":"3528","DOI":"10.3390\/ijms21103528","volume":"21","author":"G Barchiesi","year":"2020","unstructured":"Barchiesi G, Mazzotta M, Krasniqi E, Pizzuti L, Marinelli D, Capomolla E et al (2020) Neoadjuvant endocrine therapy in breast cancer: current knowledge and future perspectives. Int J Mol Sci 21(10):3528","journal-title":"Int J Mol Sci"},{"issue":"5","key":"7717_CR13","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1007\/s11864-018-0538-9","volume":"19","author":"T Reinert","year":"2018","unstructured":"Reinert T, Gon\u00e7alves R, Ellis MJ (2018) Current status of neoadjuvant endocrine therapy in early stage breast cancer. Curr Treat Options Oncol 19(5):23","journal-title":"Curr Treat Options Oncol"},{"issue":"S1","key":"7717_CR14","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s10549-007-9701-x","volume":"105","author":"MJ Ellis","year":"2007","unstructured":"Ellis MJ, Ma C (2007) Letrozole in the neoadjuvant setting: the P024 trial. Breast Cancer Res Treat 105(S1):33\u201343","journal-title":"Breast Cancer Res Treat"},{"key":"7717_CR15","doi-asserted-by":"publisher","first-page":"102669","DOI":"10.1016\/j.ctrv.2023.102669","volume":"123","author":"L Cantini","year":"2024","unstructured":"Cantini L, Trapani D, Guidi L, Boscolo Bielo L, Scafetta R, Koziej M et al (2024) Neoadjuvant therapy in hormone receptor-positive\/HER2-negative breast cancer. Cancer Treat Rev 123:102669","journal-title":"Cancer Treat Rev"},{"issue":"2","key":"7717_CR16","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1245\/s10434-016-5585-5","volume":"24","author":"A Chiba","year":"2017","unstructured":"Chiba A, Hoskin TL, Heins CN, Hunt KK, Habermann EB, Boughey JC (2017) Trends in neoadjuvant endocrine therapy use and impact on rates of breast conservation in hormone receptor-positive breast cancer: a national cancer data base study. Ann Surg Oncol 24(2):418\u2013424","journal-title":"Ann Surg Oncol"},{"issue":"22","key":"7717_CR17","doi-asserted-by":"publisher","first-page":"5108","DOI":"10.1200\/JCO.2005.04.005","volume":"23","author":"IE Smith","year":"2005","unstructured":"Smith IE, Dowsett M, Ebbs SR, Dixon JM, Skene A, Blohmer JU et al (2005) Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the immediate preoperative anastrozole, tamoxifen, or combined with tamoxifen (IMPACT) multicenter double-blind randomized trial. J Clin Oncol 23(22):5108\u20135116","journal-title":"J Clin Oncol"},{"issue":"10","key":"7717_CR18","doi-asserted-by":"publisher","first-page":"2095","DOI":"10.1002\/cncr.21872","volume":"106","author":"L Cataliotti","year":"2006","unstructured":"Cataliotti L, Buzdar AU, Noguchi S, Bines J, Takatsuka Y, Petrakova K et al (2006) Comparison of anastrozole versus tamoxifen as preoperative therapy in postmenopausal women with hormone receptor-positive breast cancer. Cancer 106(10):2095\u20132103","journal-title":"Cancer"},{"issue":"10","key":"7717_CR19","doi-asserted-by":"publisher","first-page":"5730","DOI":"10.1245\/s10434-021-10459-3","volume":"28","author":"L Cao","year":"2021","unstructured":"Cao L, Sugumar K, Keller E, Li P, Rock L, Simpson A et al (2021) Neoadjuvant endocrine therapy as an alternative to neoadjuvant chemotherapy among hormone receptor-positive breast cancer patients: pathologic and surgical outcomes. Ann Surg Oncol 28(10):5730\u20135741","journal-title":"Ann Surg Oncol"},{"issue":"12","key":"7717_CR20","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1200\/JCO.2011.38.4529","volume":"30","author":"DF Hayes","year":"2012","unstructured":"Hayes DF (2012) Targeting adjuvant chemotherapy: a good idea that needs to be proven! J Clin Oncol 30(12):1264\u20131267","journal-title":"J Clin Oncol"},{"issue":"19","key":"7717_CR21","doi-asserted-by":"publisher","first-page":"1380","DOI":"10.1093\/jnci\/djn309","volume":"100","author":"MJ Ellis","year":"2008","unstructured":"Ellis MJ, Tao Y, Luo J, A\u2019Hern R, Evans DB, Bhatnagar AS et al (2008) Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics. JNCI J Natl Cancer Inst 100(19):1380\u20131388","journal-title":"JNCI J Natl Cancer Inst"},{"key":"7717_CR22","first-page":"616","volume":"17","author":"N Arima","year":"2018","unstructured":"Arima N, Nishimura R, Osako T, Okumura Y, Nakano M, Fujisue M et al (2018) Ki-67 index value and progesterone receptor status can predict prognosis and suitable treatment in node-negative breast cancer patients with estrogen receptor-positive and HER2-negative tumors. Oncol Lett 17:616","journal-title":"Oncol Lett"},{"issue":"9","key":"7717_CR23","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1016\/S1470-2045(23)00268-1","volume":"24","author":"SA Hurvitz","year":"2023","unstructured":"Hurvitz SA, Bardia A, Quiroga V, Park YH, Blancas I, Alonso-Romero JL, Vasiliev A, Adamchuk H, Salgado M, Yardley DA, Berzoy O (2023) Neoadjuvant palbociclib plus either giredestrant or anastrozole in oestrogen receptor-positive, HER2-negative, early breast cancer (coopERA Breast Cancer): an open-label, randomised, controlled, phase 2 study. Lancet Oncol 24(9):1029\u20131041","journal-title":"Lancet Oncol"},{"key":"7717_CR24","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.3332\/ecancer.2020.1147","volume":"14","author":"E Fountzila","year":"2020","unstructured":"Fountzila E, Ignatiadis M (2020) Neoadjuvant immunotherapy in breast cancer: a paradigm shift? Ecancermedicalscience 14:1147","journal-title":"Ecancermedicalscience"},{"issue":"1","key":"7717_CR25","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1007\/s10549-022-06764-4","volume":"197","author":"JK Plichta","year":"2023","unstructured":"Plichta JK, Rushing CN, Lewis HC, Rooney MM, Blazer DG, Thomas SM et al (2023) Implications of missing data on reported breast cancer mortality. Breast Cancer Res Treat 197(1):177\u2013187","journal-title":"Breast Cancer Res Treat"},{"issue":"3","key":"7717_CR26","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1245\/s10434-024-16801-9","volume":"32","author":"K Chan","year":"2024","unstructured":"Chan K, Palis BE, Cotler JH, Janczewski LM, Zhu X, Boffa DJ, Park KU, Boughey JC, Plichta JK, In H, Nogueira LM (2024) Quality of cancer recurrence data in the national cancer database: a reappraisal of reporting readiness. Ann Surgical Oncol 32(3):1553\u20131564","journal-title":"Ann Surgical Oncol"},{"issue":"5","key":"7717_CR27","doi-asserted-by":"publisher","first-page":"1474","DOI":"10.1200\/JCO.1999.17.5.1474","volume":"17","author":"JM Harvey","year":"1999","unstructured":"Harvey JM, Clark GM, Osborne CK, Allred DC (1999) Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol 17(5):1474\u20131474","journal-title":"J Clin Oncol"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-025-07717-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10549-025-07717-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-025-07717-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,18]],"date-time":"2025-05-18T07:24:14Z","timestamp":1747553054000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10549-025-07717-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,11]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["7717"],"URL":"https:\/\/doi.org\/10.1007\/s10549-025-07717-3","relation":{},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"type":"print","value":"0167-6806"},{"type":"electronic","value":"1573-7217"}],"subject":[],"published":{"date-parts":[[2025,5,11]]},"assertion":[{"value":"24 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors report no proprietary or commercial interest in any product mentioned or concept discussed in this article. Dr. J. Plichta is a recipient of research funding by the Color Foundation (PI: Plichta). JP is a member of Editorial Committee for the American Joint Committee on Cancer (AJCC), the Breast Panel for the AJCC, and the National Comprehensive Cancer Network (NCCN) Breast Cancer Diagnosis and Screening panel. S. Thomas is a member of the Evidence-Based Medicine Core, the Breast Panel, and the Neuroendocrine Tumors Panel for the AJCC. The content of this manuscript is solely the responsibility of the authors and does not necessarily represent the official views of the NIH.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was approved by our institutional review board, and given the use of de-identified data, a waiver of consent was granted.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"This study was approved by our institutional review board, and given the use of de-identified data, a waiver of consent was granted.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}